Jaguar Animal Health (JAGX)
(Real Time Quote from BATS)
$0.07 USD
0.00 (-3.98%)
Updated Mar 28, 2024 09:54 AM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Jaguar Animal Health, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 12 | 4 | 9 | 6 |
Cost Of Goods | NA | 2 | 2 | 3 | 4 |
Gross Profit | NA | 10 | 2 | 6 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 44 | 43 | 33 | 31 |
Income After Depreciation & Amortization | 0 | -34 | -41 | -27 | -29 |
Non-Operating Income | NA | -1 | -3 | -4 | -4 |
Interest Expense | NA | 13 | 8 | 3 | 6 |
Pretax Income | NA | -48 | -53 | -34 | -39 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | -1 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -48 | -53 | -34 | -39 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -47 | -53 | -34 | -39 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -20 | -34 | -22 | -22 |
Depreciation & Amortization (Cash Flow) | NA | 14 | 7 | 5 | 7 |
Income After Depreciation & Amortization | 0 | -34 | -41 | -27 | -29 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 1.31 | 0.60 | 0.17 | 0.02 |
Diluted EPS Before Non-Recurring Items | NA | -36.18 | -88.72 | -225.56 | -1,554.29 |
Diluted Net EPS (GAAP) | NA | -36.18 | -88.72 | -225.59 | -2,032.53 |
Fiscal Year end for Jaguar Animal Health, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | NA | 2.81 | 2.68 | 1.97 | 3.26 |
Cost Of Goods | NA | 0.51 | 0.49 | 0.35 | 0.50 |
Gross Profit | NA | 2.30 | 2.19 | 1.63 | 2.77 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 11.09 | 10.29 | 11.48 | 9.05 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -8.79 | -8.10 | -9.85 | -6.28 |
Non-Operating Income | NA | 1.38 | -0.74 | -0.37 | 1.32 |
Interest Expense | NA | 0.50 | 3.45 | 2.18 | 3.26 |
Pretax Income | NA | -7.90 | -12.29 | -12.40 | -8.23 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -0.13 | -0.14 | -0.20 | -0.65 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -7.90 | -12.29 | -12.40 | -8.23 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -7.78 | -12.15 | -12.20 | -7.58 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | NA | 20.47 | 29.11 | 5.11 | NA |
Diluted EPS Before Non-Recurring Items | NA | -0.38 | -0.42 | -2.39 | NA |
Diluted Net EPS (GAAP) | NA | -0.38 | -0.42 | -2.39 | 11.94 |